Literature DB >> 23568272

Distinct and opposing roles for the phosphatidylinositol 3-OH kinase catalytic subunits p110α and p110β in the regulation of insulin secretion from rodent and human beta cells.

J Kolic1, A F Spigelman, G Plummer, E Leung, C Hajmrle, T Kin, A M J Shapiro, J E Manning Fox, P E MacDonald.   

Abstract

AIMS/HYPOTHESIS: Phosphatidylinositol 3-OH kinases (PI3Ks) regulate beta cell mass, gene transcription, and function, although the contribution of the specific isoforms is unknown. As reduced type 1A PI3K signalling is thought to contribute to impaired insulin secretion, we investigated the role of the type 1A PI3K catalytic subunits α and β (p110α and -β) in insulin granule recruitment and exocytosis in rodent and human islets.
METHODS: The p110α and p110β subunits were inhibited pharmacologically or by small hairpin (sh)RNA-mediated knockdown, and were directly infused or overexpressed in mouse and human islets, beta cells and INS-1 832/13 cells. Glucose-stimulated insulin secretion (GSIS), single-cell exocytosis, Ca(2+) signalling, plasma membrane granule localisation, and actin density were monitored.
RESULTS: Inhibition or knockdown of p110α increased GSIS. This was not due to altered Ca(2+) responses, depolymerisation of cortical actin or increased cortical granule density, but to enhanced Ca(2+)-dependent exocytosis. Intracellular infusion of recombinant PI3Kα (p110α/p85β) blocked exocytosis. Conversely, knockdown (but not pharmacological inhibition) of p110β blunted GSIS, reduced cortical granule density and impaired exocytosis. Exocytosis was rescued by direct intracellular infusion of recombinant PI3Kβ (p110β/p85β) even when p110β catalytic activity was inhibited. Conversely, both the wild-type p110β and a catalytically inactive mutant directly facilitated exocytosis. CONCLUSIONS/
INTERPRETATION: Type 1A PI3K isoforms have distinct and opposing roles in the acute regulation of insulin secretion. While p110α acts as a negative regulator of beta cell exocytosis and insulin secretion, p110β is a positive regulator of insulin secretion through a mechanism separate from its catalytic activity.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23568272     DOI: 10.1007/s00125-013-2882-4

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  47 in total

Review 1.  The role of PI3K in immune cells.

Authors:  Shigeo Koyasu
Journal:  Nat Immunol       Date:  2003-04       Impact factor: 25.606

2.  Wortmannin, a PI3-kinase inhibitor: promoting effect on insulin secretion from pancreatic beta cells through a cAMP-dependent pathway.

Authors:  K Nunoi; K Yasuda; H Tanaka; A Kubota; Y Okamoto; T Adachi; N Shihara; M Uno; L M Xu; S Kagimoto; Y Seino; Y Yamada; K Tsuda
Journal:  Biochem Biophys Res Commun       Date:  2000-04-21       Impact factor: 3.575

3.  PI 3-kinase p110beta: a new target for antithrombotic therapy.

Authors:  Shaun P Jackson; Simone M Schoenwaelder; Isaac Goncalves; Warwick S Nesbitt; Cindy L Yap; Christine E Wright; Vijaya Kenche; Karen E Anderson; Sacha M Dopheide; Yuping Yuan; Sharelle A Sturgeon; Hishani Prabaharan; Philip E Thompson; Gregg D Smith; Peter R Shepherd; Nathalie Daniele; Suhasini Kulkarni; Belinda Abbott; Dilek Saylik; Catherine Jones; Lucy Lu; Simon Giuliano; Sascha C Hughan; James A Angus; Alan D Robertson; Hatem H Salem
Journal:  Nat Med       Date:  2005-04-17       Impact factor: 53.440

4.  Direct inhibition of the signaling functions of the mammalian target of rapamycin by the phosphoinositide 3-kinase inhibitors, wortmannin and LY294002.

Authors:  G J Brunn; J Williams; C Sabers; G Wiederrecht; J C Lawrence; R T Abraham
Journal:  EMBO J       Date:  1996-10-01       Impact factor: 11.598

5.  Class IA phosphatidylinositol 3-kinase in pancreatic β cells controls insulin secretion by multiple mechanisms.

Authors:  Kazuma Kaneko; Kohjiro Ueki; Noriko Takahashi; Shinji Hashimoto; Masayuki Okamoto; Motoharu Awazawa; Yukiko Okazaki; Mitsuru Ohsugi; Kazunori Inabe; Toshihiro Umehara; Masashi Yoshida; Masafumi Kakei; Tadahiro Kitamura; Ji Luo; Rohit N Kulkarni; C Ronald Kahn; Haruo Kasai; Lewis C Cantley; Takashi Kadowaki
Journal:  Cell Metab       Date:  2010-12-01       Impact factor: 27.287

6.  A link between insulin resistance and hyperinsulinemia: inhibitors of phosphatidylinositol 3-kinase augment glucose-induced insulin secretion from islets of lean, but not obese, rats.

Authors:  W S Zawalich; K C Zawalich
Journal:  Endocrinology       Date:  2000-09       Impact factor: 4.736

7.  P110delta, a novel phosphoinositide 3-kinase in leukocytes.

Authors:  B Vanhaesebroeck; M J Welham; K Kotani; R Stein; P H Warne; M J Zvelebil; K Higashi; S Volinia; J Downward; M D Waterfield
Journal:  Proc Natl Acad Sci U S A       Date:  1997-04-29       Impact factor: 11.205

8.  Wortmannin, a microbial product inhibitor of myosin light chain kinase.

Authors:  S Nakanishi; S Kakita; I Takahashi; K Kawahara; E Tsukuda; T Sano; K Yamada; M Yoshida; H Kase; Y Matsuda
Journal:  J Biol Chem       Date:  1992-02-05       Impact factor: 5.157

9.  Gene expression heterogeneity in human islet endocrine cells in vitro: the insulin signalling cascade.

Authors:  D Muller; G C Huang; S Amiel; P M Jones; S J Persaud
Journal:  Diabetologia       Date:  2007-04-18       Impact factor: 10.122

10.  The PI 3-kinase isoforms p110(alpha) and p110(beta) have differential roles in PDGF- and insulin-mediated signaling.

Authors:  R Hooshmand-Rad; L Hájková; P Klint; R Karlsson; B Vanhaesebroeck; L Claesson-Welsh; C H Heldin
Journal:  J Cell Sci       Date:  2000-01       Impact factor: 5.285

View more
  6 in total

Review 1.  PI3Kβ-A Versatile Transducer for GPCR, RTK, and Small GTPase Signaling.

Authors:  Anne R Bresnick; Jonathan M Backer
Journal:  Endocrinology       Date:  2019-03-01       Impact factor: 4.736

2.  PI3K and AKT at the Interface of Signaling and Metabolism.

Authors:  Giovanni Solinas; Barbara Becattini
Journal:  Curr Top Microbiol Immunol       Date:  2022       Impact factor: 4.737

3.  Insulin secretion induced by glucose-dependent insulinotropic polypeptide requires phosphatidylinositol 3-kinase γ in rodent and human β-cells.

Authors:  Jelena Kolic; Aliya F Spigelman; Alannah M Smith; Jocelyn E Manning Fox; Patrick E MacDonald
Journal:  J Biol Chem       Date:  2014-10-06       Impact factor: 5.157

4.  PI3 kinases p110α and PI3K-C2β negatively regulate cAMP via PDE3/8 to control insulin secretion in mouse and human islets.

Authors:  Jelena Kolic; Jocelyn E Manning Fox; Oleg G Chepurny; Aliya F Spigelman; Mourad Ferdaoussi; Frank Schwede; George G Holz; Patrick E MacDonald
Journal:  Mol Metab       Date:  2016-05-11       Impact factor: 7.422

Review 5.  For Better or Worse: The Potential for Dose Limiting the On-Target Toxicity of PI 3-Kinase Inhibitors.

Authors:  Christina M Buchanan; Kate L Lee; Peter R Shepherd
Journal:  Biomolecules       Date:  2019-08-22

6.  BLX-1002 restores glucose sensitivity and enhances insulin secretion stimulated by GLP-1 and sulfonylurea in type 2 diabetic pancreatic islets.

Authors:  Qimin Zhang; Fan Zhang; Ake Sjöholm
Journal:  Physiol Rep       Date:  2014-05-28
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.